Novartis Korea, Handok sign Galvus co-promotion deal

Novartis Korea and Handok Pharm entered into an agreement on January 28 for the co-promotion of Galvus (vildagliptin) to treat a wide range of patients with type 2 diabetes, a progressive disease estimated to affect more than 27 million people in Korea.

Galvus is a member of a new class of medicines called DPP-4 inhibitors. This medicine is well tolerated in patients with mild renal impairme...